An official website of the United States government
Home
Name
Lumisight
Alternate Names
Pegulicianine
Abbreviations
None
Category
Ancillary Agent
Subcategory
None
NSC Number
None
Primary Site
Breast
Histology
None
Remarks
April 18, 2024 FDA has approved Lumisight (pegulicianine) in adults with breast cancer to assist the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery. Lumisight is a fluorescent imaging drug that is administered in the form of an intravenous injection before surgery.
Lumisight is used with the Lumicell Direct Visualization System (DVS) or another fluorescence imaging device that is FDA-approved for use with pegulicianine for breast lumpectomy surgery.
This is a diagnostic testing agent and not a drug but included in SEER*RX as reference.
Lumisight is used with the Lumicell Direct Visualization System (DVS) or another fluorescence imaging device that is FDA-approved for use with pegulicianine for breast lumpectomy surgery.
This is a diagnostic testing agent and not a drug but included in SEER*RX as reference.
Coding
This drug should NOT be coded
